New hope for Tough-to-Treat bile duct cancer
NCT ID NCT05994001
Summary
This study is testing a new combination of two drugs, candonilimab and LM-302, for people with advanced bile duct cancer that has continued to grow despite standard chemotherapy and immunotherapy. The goal is to see if this combination can shrink tumors and control the disease for longer. The trial is for patients whose cancer cells test positive for a specific marker called Claudin 18.2.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.